Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632381 · ClinicalTrials.gov registry record · Phase 1
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
A Phase 1 study, sponsored by Effector Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04632381 is a Phase 1 study that has completed, run by Effector Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT04632381, a Phase 1 study, has completed, sponsored by Effector Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.
Interventions
- DRUG Placebo
- DRUG Zotatifin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04632381
The ClinicalTrials.gov registry entry for NCT04632381 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04632381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04632381 about?
NCT04632381 is a clinical study titled "Intravenous Zotatifin in Adults With Mild or Moderate COVID-19". To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.
What is the current status of trial NCT04632381?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-07-01. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT04632381?
The interventions under investigation include: Placebo (DRUG), Zotatifin (DRUG).
Who is sponsoring clinical trial NCT04632381?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.